Nutritional Growth Solutions has appointed director Manik Pujara as interim CEO and CFO, replacing Andrew Grover who remains as nonexecutive chair. This leadership shuffle coincides with ongoing exploration of corporate opportunities.
- Manik Pujara assumes interim CEO and CFO roles
- Andrew Grover steps down as interim CEO but stays nonexecutive chair
- No remuneration changes for Pujara
- Leadership change amid corporate opportunity exploration
- Follows recent capital raise and cost-saving initiatives
Director Steps Into Dual Executive Roles
Nutritional Growth Solutions (ASX:NGS) has reshuffled its leadership, appointing director Manik Pujara as interim CEO and CFO. This move comes as the company continues to pursue new corporate opportunities, signaling a period of strategic reassessment. Pujara’s remuneration remains unchanged despite the expanded responsibilities.
Andrew Grover Steps Back to Chair Role
Andrew Grover, who had been serving as interim CEO since late 2025, has stepped down from the executive role but retains his position as nonexecutive chair. Grover’s tenure as interim CEO followed the departure of former CEO Stephen J. Turner and was part of a broader leadership refresh designed to stabilise the company during a transitional phase.
Leadership Changes Amid Ongoing Growth Efforts
This leadership update arrives after NGS secured a $2 million capital raise in early 2026 aimed at accelerating growth and improving cash flow. The company has also identified structural cost savings of US$600,000 annually, reflecting an ongoing effort to streamline operations. These moves suggest NGS is positioning itself carefully to capitalise on its niche in pediatric nutrition, particularly targeting the underserved three-to-twelve-year-old segment.
With Pujara now at the helm of both CEO and CFO duties, investors will be watching for clarity on how the company intends to leverage these corporate opportunities and whether a permanent executive appointment will follow. The change also raises questions about the governance balance given the concentration of executive roles in a single individual.
NGS’s focus on clinically tested nutritional supplements for children positions it uniquely in a market largely dominated by adult and infant products. The ongoing leadership transition and strategic initiatives will be critical to watch as the company seeks to expand its footprint in the competitive health and nutrition sector.
This announcement ties back to the company’s earlier leaner path to growth with $2m capital raise, suggesting a continued emphasis on financial discipline alongside strategic exploration.
Bottom Line?
Pujara’s dual interim role marks a pivotal moment for NGS, with the company’s next steps on corporate opportunities set to test its strategic agility.
Questions in the middle?
- How long will Pujara serve in the interim CEO and CFO capacities?
- What specific corporate opportunities is NGS exploring under the new leadership?
- Will the board seek to separate the CEO and CFO roles again to strengthen governance?